glp-1 agonist. PDB-101: Molecule of the Month: Receptor Agonists GLP-1 and Dual GIP/GLP-1 Agonists
Description
Theory 2: GLP-1 is a miraculous moderation molecule, and it has docking portals all throughout the body that reduce inflammation
Sheets C, Peden M, Guy J
However, Novo Nordisk is expected to emerge as the leading company, having a large portfolio of GLP1 drugs, and is expected to capture 55 per cent of the market share in 2029.
Reproduced from Wikipedia Commons
Semaglutide and the risk of diabetic retinopathycurrent perspective
Cureus [Internet], (2023)
